X0508 4 2025-09-15 0001034842 RIGEL PHARMACEUTICALS INC RIGL 0001846460 Rojkjaer Lisa RIGEL PHARMACEUTICALS, INC. 611 GATEWAY BLVD, SUITE 900 SOUTH SAN FRANCISCO CA 94080 true EVP, Chief Medical Officer false Employee Stock Option (right to buy) 22.49 2025-09-15 4 A 0 7394 0 A 2035-01-29 Common Stock 7394 7394 D The Reporting Person was granted a stock option with a performance-based condition with respect to 7,394 shares of the Issuer's common stock on January 29, 2025. The exercise price of this option is $22.49, which is the closing price of the Issuer's common stock on Nasdaq on the date of grant. In light of the performance-based vesting condition, this grant was not reportable under Section 16 until the performance metric was satisfied. On September 15, 2025, it was determined that the performance metric had been met. The option was fully vested on September 15, 2025, the date the determination was made that the performance metric had been met. /s/ Raymond Furey (Attorney-in-Fact) 2025-09-17